MORGAN STANLEY PLC/CALL/ABBOTT LABORATORIES/160/0.1/19.09.25 Stock

Warrant

DE000ME5G3T4

Market Closed - Börse Stuttgart 03:22:34 2024-07-05 pm EDT
0.084 EUR +37.70% Intraday chart for MORGAN STANLEY PLC/CALL/ABBOTT LABORATORIES/160/0.1/19.09.25
Current month+12.00%
1 month+12.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-07-05 0.084 +37.70%
24-07-04 0.061 -15.28%
24-07-03 0.072 -4.00%
24-07-02 0.075 +2.74%
24-07-01 0.073 -2.67%

Delayed Quote Börse Stuttgart

Last update July 05, 2024 at 03:22 pm EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying ABBOTT LABORATORIES
Issuer Morgan Stanley
WKN ME5G3T
ISINDE000ME5G3T4
Date issued 2023-12-15
Strike 160 $
Maturity 2025-09-19 (439 Days)
Parity 10 : 1
Emission price 0.14
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.31
Lowest since issue 0.059
Spread 0.003
Spread %3.30%

Company Profile

Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows: - diagnostic systems and instruments (39.1%); - vascular devices (24.7%): endoprosthetic systems, dilation catheters, arterial closures, etc.; - nutrition products (12.1%): pediatric nutrition products, nutritional supplements, and dietetic products; - medicine (8.2%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.; - other (15.9%). Net sales are distributed geographically as follows: the United States (38.5%), Germany (5.8%), China (5.6%), India (4.4%), Switzerland (4.1%), Japan (3.8%), Netherlands (2.7%) and others (35.1%).
Sector
-
More about the company

Ratings for Abbott Laboratories

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Abbott Laboratories

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
104 USD
Average target price
124.9 USD
Spread / Average Target
+20.09%
Consensus